MedImmune Inc.

Dr. Benes described the work of the final speaker, Christopher A. Walsh, M.D., Ph.D., as an appropriate follow-up to Dr. Kuperberg's: he is mapping the genes involved in the development of the cerebral cortex to try to understand the disruptions that underlie developmental brain disorders. Dr. Walsh is chief of the division of genetics at Children's Hospital, Boston, chief of neurogenetics in the department of neurology at the Howard Hughes Medical Institute/Beth Israel Deaconess Medical Center, Bullard Professor of Neurology at Harvard Medical School, and director of its combined M.D.-Ph.D. program. His work has garnered widespread recognition, including a NARSAD Independent Investigator Award in 1998. Dr. Walsh began by stressing that disorders related to malfunction of the cerebral cortex, such as mental retardation, learning disorders, epilepsy, autism and schizophrenia, are all more or less genetically based and extremely complex. To get a handle on the problem, he and his colleagues started by studying simpler abnormalities of the cortex related to size or gray-matter folding, working mostly with patients in the Middle East, where populations tend to be more isolated, marriage between relatives is common and families large, thus providing a large and relatively homogeneous genetic pool. Through this research, Dr. Walsh stated, his team has identified many previously unknown syndromes and defined a number of them genetically. The findings from this research eventually led Dr. Walsh to contemplate the more complex challenge of autism. While twin studies and other evidence point to autism as a highly genetic disorder, Dr. Walsh explained that it has been very difficult to correlate its clinical symptoms with specific genes. Many genes are thought to be involved and different families with autistic members tend to show different genetic profiles. There are known chromosomal defects associated with the disorder, and probably complex multigenic interactions, none of which, he said, has been defined.

Armando Anido joined Auxilium as Chief Executive Officer and President and member of the Board on July 17, 2006. Mr. Anido previously served as Executive Vice President, Sales and Marketing of MedImmune, Inc. where he was also a member of that company's Executive, Product Development, and Management Committees, as well as the Chair of the Commercial Strategy Team responsible for the commercial management of MedImmune's marketed brands. He is currently a member of the Board of Directors of Adolor Corporation. Prior to MedImmune, Mr. Anido held several senior marketing positions at Glaxo Wellcome, Inc. and its predecessor companies, including Vice President, Central Nervous System Marketing and Director of HIV Marketing. Prior to Glaxo Wellcome, Mr. Anido was in various sales and marketing roles at Lederle Laboratories, culminating in the role of Vice President, Anti-Infectives. Mr. Anido holds a Bachelors of Science in Pharmacy and a Masters in Business Administration from West Virginia University.

has over 30 years of experience in building and managing the Human Resources and Environmental Health & Safety functions at MedImmune, Inc., W.R. Grace, Inc., SmithKline Beckman Corporation and American Cyanamid-Medical Group. He is responsible for HR, EH&S, and Operations at MacroGenics. As head of HR and EH&S at MedImmune, Mr.

Scott B. Townsend, Esq. has served as our General Counsel, Executive Vice President of Legal Affairs and Secretary since our merger with Cornerstone BioPharma. Before the merger, Mr. Townsend served as our Senior Vice President of Legal Affairs from March 2007 to October 2008, as our General Counsel from June 2006 to October 2008 and as our Secretary from September 2004 to October 2008. Mr. Townsend served as our Vice President of Legal Affairs from August 2004 to March 2007. From August 2000 to August 2004, Mr. Townsend was employed by the law firm Wilmer Cutler Pickering Hale and Dorr LLP (formerly known as Hale and Dorr LLP) as a junior partner from May 2002 to August 2004 and as an associate from August 2000 to May 2002. Mr. Townsend was an associate with the law firm Kilpatrick Stockton LLP in Charlotte, North Carolina, from July 1999 to July 2000 and an associate with the law firm Goodwin Procter LLP in Boston, Massachusetts, from September 1997 to July 1999. Mr. Townsend holds an A.B. in Economics and Government from Bowdoin College and a J.D. from The University of Virginia School of Law.

Gregory LaRosa, Ph.D. has served as our Vice President, Research since December 2004 and as our Senior Director, Drug Discovery from April 2003 to December 2004. From December 1999 to April 2003, Dr. LaRosa served as Senior Director of Immunopharmacology at Millennium Pharmaceuticals, Inc., a pharmaceutical company. From September 1994 to December 1999, Dr. LaRosa served in a variety of research positions, including Senior Director of Receptor Pharmacology, for LeukoSite, Inc., a biotechnology company. From 1988 to September 1994, Dr. LaRosa held several research posts at Repligen, Corp., a biotechnology company. Dr. LaRosa holds a B.A. in Genetics and Development from Cornell University and a Ph.D. in Cell and Developmental Biology from Harvard University.

Robert H. Zeiger has served as a member of our board of directors since October 2004. He served as lead independent director from February 2005 to June 2006 and as Executive Chairman of the Company and Chairman of the Board from June 2006 to October 2006. From October 2000 to the present, Mr. Zeiger has served as a marketing consultant for a number of privately-held pharmaceutical companies. From May 1995 to October 2000, Mr. Zeiger served in a variety of roles for Viragen, Inc., a biopharmaceutical company, including Chief Executive Officer and Chief Operating Officer from May 1995 to September 1998 and Vice Chairman of the Board of Directors from October 1998 to October 2000. From 1985 to 1994, Mr. Zeiger served in a variety of roles for Glaxo, Inc., a pharmaceutical company, including Vice President and General Manager of Glaxo Dermatology, Allen & Hanbury and Glaxo Pharmaceuticals. From 1979 to 1985, Mr. Zeiger served as Vice President of Marketing and Sales with Stiefel Laboratories, an international dermatology company. From 1971 to 1979, Mr. Zeiger served as National Sales Manager for Knoll Pharmaceutical, a pharmaceutical company. Mr. Zeiger holds a B.S. in marketing from Loyola University.